Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: summary of national findings, NSDUH series H-41. Rockville: Substance Abuse and Mental Health Services Administration; 2011.
Gfroerer J, Epstein J. Marijuana initiates and their impact on future drug abuse treatment need. Drug Alcohol Depend. 1999;54:229–37.
Roffman R, Stephens R. Cannabis dependence: its nature, consequences and treatment. Cambridge: Cambridge University Press; 2006.
Budney A, Radonovich K, Higgins S, Wong C. Adults seeking treatment for marijuana dependence: a comparison with cocaine-dependent treatment seekers. Exp Clin Psychopharmacol. 1998;6:419–26.
Moore B, Budney A. Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat. 2003;25:85–9.
Stephens R, Roffman R, Simpson E. Adult marijuana users seeking treatment. J Consult Clin Psychol. 1993;61:1100–4.
Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol. 2004;72:455–66.
Monti J. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology. 1977;55:263–5.
Bolla K, Lesage S, Gamalso C, Neubauer D, Funderburk F, Cadet J, et al. Sleep disturbance in heavy marijuana users. Sleep. 2008;31:901–8.
Fusar-Poli P, Crippa J, Bhattacharyya S, Borgwardt S, Allen P, Martin-Santos R, et al. Distinct effect of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66:95–105.
Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Piomello D, Shiromani P. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep. 2003;26:943–7.
Cousens K, DiMascio A. Delta 9 THC as an hypnotic. An experimental study of three dose levels. Psychopharmacologia. 1973;33:355–64.
Tassinari C, Ambrosetto G, Peraita-Adrado MR, Gastaut H. The neuropsychiatric syndrome of delta-9-tetrahydrocannabinol and cannabis intoxication in naïve subjects: a clinical and polygraphic study during wakefulness and sleep. In: Braude M, Szara S, editors. Pharmacology of marijuana. New York: Raven; 1976. p. 357–75.
Gillin J, Kotin J, Post R. Sleep during one week of administration of delta-9-tetrahydrocanabinol to psychiatric patients. J Sleep Res. 1972;1:44.
Bobon D, Schulz H, Mattke D, Simonova O. Influence of synthetic-8-tetrahydrocannabinol on all-night sleep EEG in man. In: Jovanovic U, editor. The nature of sleep. Stuttgart: Fischer; 1973.
Weisz D, Gunnell D, Teyler T, Vardaris R. Changes in hippocampal CA1 population spikes following administration of delat-9-THC. Brain Res Bull. 1982;8:155–62.
Nicholson A, Turner C, Stone B, Robson P. Effect of Δ-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24:305–13.
Moreton J, Davis W. Electroencephalographic study of the effects of tetrahydrocannabinols on sleep in the rat. Neuropharmacology. 1973;12:897–907.
Bolla K, Brown K, Eldreth D, Tate K, Cadet J. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59:1337–43.
Chuah Y, Venlatraman V, Dinges D, Chee M. The neural basis of interindividual variability in inhibitory efficiency after sleep deprivation. J Neurosci. 2006;26:7156–62.
Drummond S, Smith M, Orff H, Chengazi V, Perlis M. Functional imaging of the sleeping brain: review of findings and implications for the study of insomnia. Sleep Med Rev. 2004;8:227–42.
Muzur A, Pace-Schott E, Hobson J. The prefrontal cortex in sleep. Trends Cogn Sci. 2002;6:475–81.
Eldreth D, Matochik J, Cadet J, Bolla K. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimaging. 2004;23:914–20.
Volkow N, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A, et al. Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res. 1996;67:29–38.
Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict. 2013;22:277–84.
Bonn-Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. J Trauma Stress. 2007;20:577–86.
Buckner JD, Schmidt NB, Bobadilla L, Taylor J. Social anxiety and problematic cannabis use: evaluating the moderating role of stress reactivity and perceived coping. Behav Res Ther. 2006;44:1007–15.
Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH. Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012;4:649–59.
Cooper M. Motivations for alcohol use among adolescents: Development and validation of a four-factor model. Psychol Assess. 1994;6:117–28.
Fox C, Towe S, Stephens R, Walker D, Roffman R. Motives for cannabis use in high-risk adolescent users. Psychol Addict Behav. 2011;25:492–500.
Hides L, Lubman D, Cosgrave E, Buckby J, Killackey E, Yung A. Motives for substance use among young people seeking mental health treatment. Early Interv Psychiatr. 2008;2:188–94.
Johnson K, Mullin J, Marshall E, Bonn-Miller M, Zvolensky M. Exploring the mediational role of coping motives for marijuana use in terms of the relation between anxiety sensitivity and marijuana dependence. Am J Addict. 2010;19:277–82.
Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136:162–5. Improvement in sleep is the primary motivation for medical cannabis use among medical cannabis users with elevated symptoms of PTSD.
Russo E, Guy G, Robson P. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4:1729–43.
Schierenbeck T, Riemann D, Berger M, Homyak M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12:381–9.
Halikas J, Weller R, Morse C, Hoffmann R. A longitudinal study of marijuana effects. Int J Addict. 1985;20:701–11.
Boys A, Marsden J, Strang J. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res. 2001;16:457–69.
Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction. 1998;93:837–46.
Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Self-reported cannabis use characteristics, patterns, and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014;40:23–30.
Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Pol. 2013;24:511–6.
Schaub M, Fanghaenel K, Stohler R. Reasons for cannabis use: Patients with schizophrenia versus matched healthy controls. Aust N Z J Psychiatr. 2008;42:1060–5.
Bonn-Miller MO, Babson KA, Vujanovic AA, Feldner MT. Sleep problems and PTSD symptoms interact to predict marijuana use coping motives: a preliminary investigation. J Dual Diagn. 2010;6:111–22.
Budney A, Hughes J, Moore B, Novy P. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry. 2001;58:917–24.
Budney A, Moore B, Vandrey R, Hughes J. The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003;112:393–402.
Budney A, Vandrey R, Hughes J, Thostenson J, Bursac Z. Comparison of cannabis and tobacco withdrawal syndrome. Am J Psychiatry. 2008;161:1967–77.
Budney A, Vandrey R, Hughes J, Moore B, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86:22–9.
Haney M, Ward A, Comer S, Foltin R, Fischman M. Abstinence symptoms following oral THC administration to humans. Psychopharmacology. 1999;141:385–94.
Hart C, Ward A, Haney M, Comer S, Foltin R, Fischman M. Comparison of smoked marijuana and oral Δ9-tetrahydrocannabinol in humans. Psychopharmacology. 2002;164:407–15.
Haney M, Hart C, Vosburg S, Nasser J, Bennett A, Zubaran C, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29:58–70.
Haney M, Hart C, Vosburg S, Comer S, Reed S, Foltin R. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2008;197:157–68.
Vandrey R, Smith M, McCann U, Budney A, Curran E. Sleep disturbance and the effects of extended release zolpidem during cannabis withdrawal. Drug Alcohol Depend. 2011;117:38–44. Cannabis use cessation increases sleep disturbances, whereas intervention to address sleep problems attenuates this finding. Sleep interventions may be a beneficial addition to CUD treatment.
Haney M. Self-administration of cocaine, cannabis, and heroin in the human laboratory: benefits and pitfalls. Addict Biol. 2009;14:9–21.
Babson K, Boden M, Bonn-Miller M. The impact of perceived sleep quality and sleep efficiency/duration on cannabis use during a self-guided quit attempt. Addict Behav. 2013;38:2707–13. Veterans with poor sleep quality prior to a quit attempt have less of a reduction in cannabis use during a quit attempt compared with those with relatively better sleep.
Babson KA, Boden MT, Harris AHS, Stickle TR, Bonn-Miller MO. Poor sleep quality as a risk factor for lapse following a cannabis quit attempt. J Subst Abuse Treat. 2013;44:438–43. Veterans with poor sleep prior to a cannabis quit attempt are at greater risk of lapse/relapse to cannabis use within the first 2 days of the quit attempt.
Copersino M, Boyd S, Tashkin D, Huestis M, Heishman S, Dermans J, et al. Cannabis withdrawal among non treatment-seeking adult cannabis user. Am J Addict. 2006;15:8–14.
Levin K, Copersino M, Heishman S, Liu F, Kelly D, Boggs D, et al. Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend. 2010;111:120–7.
Haney M, Hart C, Vosburg S, Comer S, Reed S, Cooper Z, et al. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2010;211:233–44.
Cooper Z, Foltin R, Hart C, Vosburg S, Comer S, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol. 2013;18:993–1002.
Morgenthaler T, Kraemer M, Alessi C, Friedman L, Boehlecke B, Brown T, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An AASM report. Sleep. 2006;29:1415–9.
Morin C, Culbert J, Schwartz S. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151:1172–80.
Roehrs T, Roth T. Insomnia pharmacotherapy. Neurotherapeutics. 2012;9:728–38.
Morin C, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;28:991–9.
McClusky H, Milby J, Switzer P, William V, Wooten V. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. Am J Psychiatry. 1991;148:121–6.
Morin C, Vallieres A, Guay B, Ivers H, Savard J, Merette C, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia. A randomized controlled trial. JAMA. 2009;301:2005–15.
Currie S, Clark S, Hodgins D, El-Guebaly N. Randomized controlled trial of brief cognitive-behavioural interventions for insomnia in recovering alcoholics. Addiction. 2004;99:1121–32.
Arnedt J, Conroy D, Rutt J, Aloia M, Brower K, Armitage R. An open trial of cognitive-behavioral treatment for insomnia comorbid with alcohol dependence. Sleep Med. 2007;8:176–80.